ClearPoint Neuro, Inc. files with the SEC under CIK 0001285550 and is classified as surgical and medical instruments and apparatus. We track it alongside the rest of the Health Care sector.
CLPT Form 4 activity by transaction type, last 90 days
Form 4 transaction type
Transactions
Shares
Total value
Grant or award
2
1,312
Option exercise
2
25,034
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
CLPT insider transactions (Form 4)
50
98 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 3.
Footnote F1 (price): These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the… Full note on SEC EDGAR
Footnote F1 (price): These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the… Full note on SEC EDGAR
Footnote F1 (shares): Mr. Burnett paid the exercise price for the options in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction.
Footnote F1 (price): These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the… Full note on SEC EDGAR
Footnote F1 (price): These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the… Full note on SEC EDGAR
Footnote F1 (price): The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. In accordance with the ESPP, these shares were purchased at… Full note on SEC EDGAR
Footnote F1 (price): The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. In accordance with the ESPP, these shares were purchased at… Full note on SEC EDGAR
Footnote F1 (price): The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. In accordance with the ESPP, these shares were purchased at… Full note on SEC EDGAR
Footnote F2 (price): Represents a weighted average sales price per share. The shares were sold at prices ranging from $19.15 to $19.54. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the… Full note on SEC EDGAR
Footnote F2 (price): Represents a weighted average sales price per share. The shares were sold at prices ranging from $17.35 to $18.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the… Full note on SEC EDGAR
Footnote F3 (price): Represents a weighted average sales price per share. The shares were sold at prices ranging from $17.75 to $18.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the… Full note on SEC EDGAR
Footnote F1 (shares): This option was previously reported as covering 20,000 shares at an exercise price of $0.25 per share, but was adjusted to reflect the stock split that occurred on July 27, 2016.
Footnote F2 (price): Represents a weighted average sales price per share. The shares were sold at prices ranging from $12.04 to $12.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the… Full note on SEC EDGAR
Footnote F1 (price): Represents a weighted average sales price per share. The shares were sold at prices ranging from $11.57 to $11.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the… Full note on SEC EDGAR
Footnote F1 (price): Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date… Full note on SEC EDGAR
Footnote F1 (price): Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date… Full note on SEC EDGAR
Footnote F3 (price): Represents a weighted average sales price per share. The shares were sold at prices ranging from $11.04 to $11.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the… Full note on SEC EDGAR
Footnote F1 (price): Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date… Full note on SEC EDGAR
Footnote F1 (price): Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date… Full note on SEC EDGAR
Footnote F1 (price): Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date… Full note on SEC EDGAR
Footnote F1 (price): Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date… Full note on SEC EDGAR
Footnote F1 (price): Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date… Full note on SEC EDGAR
Footnote F1 (price): These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the… Full note on SEC EDGAR
Footnote F1 (price): These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the… Full note on SEC EDGAR
Footnote F1 (price): These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the… Full note on SEC EDGAR
Footnote F1 (shares): Mr. Burnett paid the exercise price for the options in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction.
Footnote F1 (price): Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
Footnote F2 (shares): Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.
An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
ClearPoint Neuro, Inc. (CLPT) had 3 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for CLPT runs to 98 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CLPT stock?
No insider purchases of CLPT were filed in the last 90 days.
How many insiders are selling CLPT stock?
No insider sales of CLPT were filed in the last 90 days. 17 sales are on record for this company.
Where can I see CLPT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CLPT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.